Brain training plus drug may ease chemo nerve damage
NCT ID NCT04560673
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether combining neurofeedback (a brain-wave training therapy) with the drug duloxetine can better relieve nerve pain caused by chemotherapy than either treatment alone. About 336 cancer survivors with persistent nerve pain will be randomly assigned to one of three groups: duloxetine only, neurofeedback only, or both together. The goal is to see if the combination reduces pain unpleasantness and improves quality of life after five weeks of treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
duloxetine and neurofeedback training
What this could lead to
If it works, this could offer a new way to manage nerve pain from chemotherapy without relying solely on medication.
What could go wrong
This is a mid-stage trial with 336 participants, so results are not yet proven. The combination may not be more effective than duloxetine alone, and neurofeedback requires time and commitment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Harris Health System (LBJ)
Houston, Texas, 77026, United States
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States